Z49.2. Other dialysis
Conditions
Interventions
Intervention 1: In the intervention group, patients received 400 mg of standard garlic powder extract tablets twice aday for 8 weeks. each tablet contains 1000 micrograms of alliin.
The drug was prod
Treatment - Drugs
In the intervention group, patients received 400 mg of standard garlic powder extract tablets twice aday for 8 weeks. each tablet contains 1000 micrograms of alliin.
The drug was produced by the Ami
In the control group, The placebo was prescribed.The placebo was completely similar to the original drug and it was made of starch.and it also The drug was produced by the Amin pharmaceutical company.
Sponsors
Shahid Modarres Clinical Research Center,Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Exclusion criteria : Recent use of medicines and foods that contain garlic; sensitivity to garlic; history of bleeding; disorders and use of warfarin; history of infection or hospitalization inthe last 3 months; unwillingness to continue to participate in the research project; history of gastric bypass; do not use more than 80% of medicine. Inclusion criteria : age above 18; six months have passed since the onset of peritoneal dialysis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid profil,TG.CHOL.HDL.LDL in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;IL6 in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;ESR in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Albumin in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;CRP in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Ferritin in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Homocysteine in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;CBC.diff in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Serum iron in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Peritoneal equilibration test in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Blood pressure in control group. Timepoint: Before and after intervention. Method of measurement: Sphygmomanometer.;Weight in control group. Timepoint: Before and after intervention. Method of measurement: Scale.;ASt in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;ALT in control group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Lipid profil,TG.CHOL.HDL.LDL. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;IL6 in case group in cases group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;ESR in cas3 group. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement.;Albumin in case group. T | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhesam Alirezaei
Shahid Beheshti University of Medical Sciences
Outcome results
None listed